Durable mCRC responses spur FDA talks for Oncolytics Biotech (NASDAQ: ONCY)
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Oncolytics Biotech Inc. reported new clinical data from its REO 022 study in second-line RAS-mutant, microsatellite-stable metastatic colorectal cancer. Pelareorep-based combination therapy achieved a 19.5‑month median duration of response, compared with historical benchmarks of about 4–6 months in this setting.
The regimen of pelareorep, bevacizumab, and FOLFIRI showed a 33% objective response rate, versus 6–11% reported for standard care. The company is enrolling a randomized Phase 2 trial in this population and is actively engaged with the FDA to discuss a potential accelerated approval pathway based on response durability and time‑to‑event endpoints.
Positive
- Strong durability and response data in 2L RAS-mutant MSS mCRC: Pelareorep-based therapy showed a 19.5‑month median duration of response and a 33% objective response rate, markedly above historical 4–6‑month durability and 6–11% response benchmarks in this difficult colorectal cancer setting.
- Regulatory momentum via FDA engagement: The company is actively engaging with the FDA to discuss a potential accelerated approval pathway for pelareorep in second-line RAS-mutant MSS metastatic colorectal cancer, aligned with its ongoing randomized Phase 2 study.
Negative
- None.
Insights
Pelareorep shows markedly longer responses in tough colorectal cancer setting, supporting talks on accelerated approval.
Oncolytics Biotech released REO 022 data in second-line RAS-mutant MSS metastatic colorectal cancer. Pelareorep plus bevacizumab and FOLFIRI delivered a 19.5‑month median duration of response, far above historical 4–6‑month benchmarks, and an objective response rate of 33% versus historical 6–11%.
The company is running a randomized Phase 2 study in this population and is in dialogue with the FDA about a potential accelerated approval pathway using durability and time‑to‑event endpoints. Actual regulatory outcomes will depend on results from this ongoing trial and broader safety and efficacy data across gastrointestinal cancers.
8-K Event Classification
2 items: 8.01, 9.01
2 items
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Median duration of response: 19.5 months
Historical duration benchmark: 4–6 months
Objective response rate: 33%
+2 more
5 metrics
Median duration of response
19.5 months
Second-line KRAS-mutant MSS mCRC patients in REO 022
Historical duration benchmark
4–6 months
Historical median duration of response in same setting
Objective response rate
33%
Pelareorep + bevacizumab + FOLFIRI in REO 022
Historical ORR benchmark
6–11%
Standard of care in second-line MSS mCRC
Regulatory pathway
Potential accelerated approval
Being discussed with FDA for 2L RAS-mutant MSS mCRC
Key Terms
median duration of response, objective response rate, microsatellite-stable, accelerated approval pathway, +1 more
5 terms
median duration of response medical
"Pelareorep-based combination therapy demonstrated a 19.5-month median duration of response in second-line"
Median duration of response is the midpoint time that a beneficial effect from a treatment lasts among patients who showed a measurable improvement; half of responders saw the effect stop sooner, half later. Investors care because it shows how durable a therapy’s benefit is — like the typical lifespan of a product’s performance — which affects expected clinical value, market demand, pricing power and reimbursement prospects.
objective response rate medical
"Additional data from this study include an objective response rate of 33% for patients receiving"
The objective response rate (ORR) is the percentage of patients in a clinical trial whose tumors measurably shrink or disappear according to preset rules. Investors use it as a quick, objective signal of a drug’s ability to produce a clear treatment effect—like counting how many plants visibly respond after applying a new fertilizer—and higher ORR can improve odds of regulatory approval, commercial success, and company valuation.
microsatellite-stable medical
"demonstrating meaningful and sustained clinical benefit in patients with RAS-mutant, microsatellite-stable"
Microsatellite-stable describes tumors whose short, repeated stretches of DNA remain unchanged, meaning the cell’s internal “proofreader” is effectively catching copying errors. Investors care because this molecular trait affects which therapies and clinical trials are likely to work — some immunotherapies and targeted drugs perform differently in stable versus unstable tumors, influencing a drug’s market potential, trial success and regulatory path.
accelerated approval pathway regulatory
"Company Engaged with FDA to Support Potential Accelerated Approval Pathway in 2L RAS-Mutant MSS mCRC"
The accelerated approval pathway is a process that allows new medicines to be approved more quickly based on early evidence that they may be effective, rather than waiting for full proof. This can help patients access promising treatments faster, but it also means ongoing studies are needed to confirm the benefits. For investors, it highlights potential faster market entry and earlier revenue opportunities, along with some uncertainty about long-term outcomes.
Fast Track designation regulatory
"pelareorep has received Fast Track designation from the FDA for colorectal and pancreatic cancer"
A "fast track designation" is a process that speeds up the review and approval of a product or project, allowing it to reach the market or be completed more quickly than usual. For investors, it can signal that a product may become available sooner, potentially leading to earlier revenue or benefits, and indicating a priority status that might influence company performance and market opportunities.
FAQ
What key colorectal cancer results did Oncolytics Biotech (ONCY) report in REO 022?
Oncolytics reported pelareorep-based therapy achieved a 19.5‑month median duration of response in second-line KRAS-mutant MSS metastatic colorectal cancer, with a 33% objective response rate, compared with historical 4–6‑month durability and 6–11% response benchmarks for standard therapies.
How does pelareorep’s performance compare to historical benchmarks in 2L RAS-mutant MSS mCRC for ONCY?
Pelareorep-based therapy showed a 19.5‑month median duration of response versus historical 4–6 months and a 33% objective response rate versus historical 6–11%, suggesting substantially longer and more frequent responses than typical second-line treatments in this colorectal cancer setting.
Is Oncolytics Biotech (ONCY) pursuing accelerated approval for pelareorep in colorectal cancer?
Oncolytics is engaging with the U.S. FDA to explore a potential accelerated approval pathway in second-line RAS-mutant MSS metastatic colorectal cancer, using response durability and time‑to‑event endpoints from its ongoing randomized Phase 2 study as the clinical basis.
What ongoing trial is evaluating pelareorep in colorectal cancer for Oncolytics Biotech (ONCY)?
The company is enrolling a randomized Phase 2 trial of pelareorep combined with FOLFIRI and bevacizumab in second-line RAS-mutant MSS metastatic colorectal cancer, designed to generate durability and time‑to‑event data that may support registration discussions with regulators, including the FDA.
In which cancers has pelareorep previously shown encouraging results for Oncolytics Biotech (ONCY)?
Pelareorep has demonstrated encouraging results in multiple first-line pancreatic cancer studies, two randomized Phase 2 metastatic breast cancer trials, and early-phase studies in anal and colorectal cancers, supporting its broader development in metastatic gastrointestinal indications with significant unmet medical need.
What regulatory designations has pelareorep received in gastrointestinal cancers for ONCY?
Pelareorep has received Fast Track designation from the U.S. FDA for colorectal and pancreatic cancer, reflecting regulators’ recognition of its potential to address high unmet need in metastatic gastrointestinal tumors when combined with chemotherapy and/or checkpoint inhibitors.